| Literature DB >> 29954945 |
Rodrigo Pacheco Silva-Aguiar1, Nathália C F Bezerra1, Miguel C Lucena1, Gabriela M Sirtoli1, Roberto T Sudo2, Gisele Zapata-Sudo2, Christina M Takiya1, Ana Acacia S Pinheiro1, Wagner Barbosa Dias1, Celso Caruso-Neves3,4.
Abstract
Hypertensive individuals are at greater risk for developing chronic kidney disease (CKD). Reducing proteinuria has been suggested as a possible therapeutic approach to treat CKD. However, the mechanisms underlying the development of proteinuria in hypertensive conditions are incompletely understood. Cardiac and vascular dysfunction is associated with changes in the O-GlcNAcylation pathway in hypertensive models. We hypothesized that O-GlcNAcylation is also involved in renal damage, especially development of proteinuria, associated with hypertension. Using the spontaneously hypertensive rat (SHR) model, we observed higher renal cortex O-GlcNAcylation, glutamine-fructose aminotransferase (GFAT), and O-GlcNAc transferase (OGT) protein expression, which positively correlated with proteinuria. Interestingly, this was observed in hypertensive, but not pre-hypertensive, rats. Pharmacological inhibition of GFAT decreased renal cortex O-GlcNAcylation, proteinuria, and albuminuria in SHR. Using a proximal tubule cell line, we observed that increased O-GlcNAcylation reduced megalin surface expression and albumin endocytosis in vitro, and the effects were correlated in vivo Moreover, megalin is O-GlcNAcylated both in vitro and in vivo In conclusion, our results demonstrate a new mechanism involved in hypertension-associated proteinuria.Entities:
Keywords: O-GlcNAcylation; O-linked N-acetylglucosamine (O-GlcNAc); SHR; endocytosis; hypertension; kidney; megalin; proteinuria
Mesh:
Substances:
Year: 2018 PMID: 29954945 PMCID: PMC6102134 DOI: 10.1074/jbc.RA118.001746
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157